Evidence map›Paper›PMID 40166167›Full record

ArticlebioRxiv : the preprint server for biology2025

Spatial patterning of fibroblast TGFβ signaling underlies treatment resistance in rheumatoid arthritis.

Kartik Bhamidipati, Alexa B R McIntyre, Shideh Kazerounian, Gao Ce, Miles Tran, Sean A Prell, Rachel Lau, Vikram Khedgikar, Christopher Altmann, Annabelle Small and 20 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Kartik BhamidipatiDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Alexa B R McIntyreDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Shideh KazerounianDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Gao CeDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Miles TranDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Sean A PrellDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Rachel LauCentre for Experimental Medicine and Rheumatology, EULAR Centre of Excellence, William Harvey Research Institute, Queen Mary University of London, London, UK.
Vikram KhedgikarDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Christopher AltmannCollege of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Annabelle SmallCollege of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Vincent WongCollege of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Roopa MadhuDivision of Genetics, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Sonia PrestiDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Ksenia S AnufrievaDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Philip E BlazarDepartment of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Jeffrey K LangeDepartment of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Jennifer SeifertDivision of Rheumatology, The University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Accelerating Medicines Partnership: RA/SLE Network
Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP-AIM)
Larry W MorelandDivision of Rheumatology, The University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Adam P CroftRheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK.
Myles J LewisCentre for Experimental Medicine and Rheumatology, EULAR Centre of Excellence, William Harvey Research Institute, Queen Mary University of London, London, UK.
Ranjeny ThomasFrazer Institute, The University of Queensland, Woolloongabba, Queensland, Australia.
Anna H JonssonDivision of Rheumatology, The University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Costantino PitzalisCentre for Experimental Medicine and Rheumatology, EULAR Centre of Excellence, William Harvey Research Institute, Queen Mary University of London, London, UK.
Ellen M GravalleseDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Michael B BrennerDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Ilya KorsunskyDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.
Mihir D WechalekarCollege of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Kevin WeiDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA.

Funding

MECHANISMS OF ARTHRITIC &DERMATOLOGY DISORDERST32AR007530 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael B. Brenner, Ellen M Gravallese · 1986 to 2026
$10.4M
Pathogenic fibroblast differentiation in rheumatoid arthritisK08AR077037 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI WEI, KEVIN S · 2020 to 2024
$799k
NIAMS NIH HHS K08 AR077037NIAMS NIH HHS T32 AR007530
6 · The paper itself

Abstract

Treatment-refractory rheumatoid arthritis (RA) is a major unmet need, and the mechanisms driving treatment resistance are poorly understood. To identify molecular determinants of RA non-remission, we performed spatial transcriptomic profiling on pre- and post-treatment synovial tissue biopsies from treatment naïve patients who received conventional DMARDs or adalimumab for 6 months. In the baseline biopsies of non-remission patients, we identified significant expansion of fibrogenic fibroblasts marked by high expression of

Identifiers

PMID40166167
PMCPMC11956964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.